Use of test
Gene fusions involving the IGH gene at 14q32 and the FGFR3 gene at 4p16 are seen in multiple myeloma. The identification of such fusions can assist in the diagnosis and classification of this disease. This rearrangement is not easily detectable by karyotype analysis.
Presence of an IGH-FGFR3 rearrangement is a sign of poor prognosis in myeloma.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis using probes to identify fusion of the IGH with FGFR3 gene due to a t(4;14)(p16;q32) translocation.
Requesting the test
0.5 mL bone marrow in transport media.
To help ensure the quality of the test, a genetic test should be done with a dedicated sample whenever possible i.e. a sample collected specifically for that test rather than a sample that is used for multiple tests.
We recommend that the patient or another adult check the labelling of request forms and sample tubes.
2 business days.
Up to $255.
If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.